130 related articles for article (PubMed ID: 27802200)
1. Modern molecular biomarkers of head and neck cancer. Part I. Epigenetic diagnostics and prognostics: Systematic review.
Juodzbalys G; Kasradze D; Cicciù M; Sudeikis A; Banys L; Galindo-Moreno P; Guobis Z
Cancer Biomark; 2016; 17(4):487-502. PubMed ID: 27802200
[TBL] [Abstract][Full Text] [Related]
2. Genetic and proteomic biomarkers of head-and-neck cancer: A systematic review.
Kasradze D; Juodzbalys G; Guobis Z; Gervickas A; Cicciù M
J Cancer Res Ther; 2020; 16(3):410-424. PubMed ID: 32719245
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics in the diagnosis and prognosis of head and neck cancer: A systematic review.
Lim I; Tan J; Alam A; Idrees M; Brenan PA; Coletta RD; Kujan O
J Oral Pathol Med; 2024 Feb; 53(2):90-106. PubMed ID: 38316046
[TBL] [Abstract][Full Text] [Related]
4. Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy.
Hier J; Vachon O; Bernstein A; Ibrahim I; Mlynarek A; Hier M; Alaoui-Jamali MA; Maschietto M; da Silva SD
Sci Rep; 2021 May; 11(1):10012. PubMed ID: 33976322
[TBL] [Abstract][Full Text] [Related]
5. Salivary epigenetic biomarkers in head and neck squamous cell carcinomas.
Lim Y; Sun CX; Tran P; Punyadeera C
Biomark Med; 2016; 10(3):301-13. PubMed ID: 26888346
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
[TBL] [Abstract][Full Text] [Related]
8. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
Bourguignon LYW; Earle C; Shiina M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of DNA methylation for head and neck cancer varies by sample type and number of markers tested.
Ji X; Guan C; Jiang X; Li H
Oncotarget; 2016 Nov; 7(48):80019-80032. PubMed ID: 27683120
[TBL] [Abstract][Full Text] [Related]
10. Methylation as a biomarker for head and neck cancer.
Arantes LM; de Carvalho AC; Melendez ME; Carvalho AL; Goloni-Bertollo EM
Oral Oncol; 2014 Jun; 50(6):587-92. PubMed ID: 24656975
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence.
Righini CA; de Fraipont F; Timsit JF; Faure C; Brambilla E; Reyt E; Favrot MC
Clin Cancer Res; 2007 Feb; 13(4):1179-85. PubMed ID: 17317827
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic and genetic alterations-based molecular classification of head and neck cancer.
Feng Z; Xu Q; Chen W
Expert Rev Mol Diagn; 2012 Apr; 12(3):279-90. PubMed ID: 22468818
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.
Rettori MM; de Carvalho AC; Bomfim Longo AL; de Oliveira CZ; Kowalski LP; Carvalho AL; Vettore AL
Carcinogenesis; 2013 Jan; 34(1):20-7. PubMed ID: 23042095
[TBL] [Abstract][Full Text] [Related]
14. Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis.
Rapado-González Ó; Martínez-Reglero C; Salgado-Barreira Á; Santos MA; López-López R; Díaz-Lagares Á; Suárez-Cunqueiro MM
J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34206840
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Mechanisms of Human Papillomavirus-Associated Head and Neck Cancer.
Anayannis NV; Schlecht NF; Belbin TJ
Arch Pathol Lab Med; 2015 Nov; 139(11):1373-8. PubMed ID: 25978766
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
17. Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol.
Shaw P; Raymond G; Senthilnathan R; Kumarasamy C; Baxi S; Suresh D; Shetty S; Ram M R; Chandramoorthy HC; Sivanandy P; Samiappan S; Rajagopal M; Krishnan S; Jayaraj R
Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946979
[No Abstract] [Full Text] [Related]
18. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic biomarkers in colorectal cancer: premises and prospects.
Zamani M; Hosseini SV; Mokarram P
Biomarkers; 2018 Mar; 23(2):105-114. PubMed ID: 27788596
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNAs in head and neck cancer: a scoping review of methods.
Dharmawardana N; Ooi EH; Woods C; Hussey D
Clin Exp Metastasis; 2019 Jun; 36(3):291-302. PubMed ID: 30877500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
